Aoki K, Yoshida T, Kato S, Tazumi K, Sato I
Jpn Heart J. 1976 Jul;17(4):479-84. doi: 10.1536/ihj.17.479.
The Ca2+ antagonistic coronary vasodilator, Nifedipine, was sublingually administered by a dose of 30 mg to 19 patients with hypertension. Blood pressure of patients with with essential hypertension (n=14) decreased from 177 +/- 24 to 123 +/- 13 mmHg systolic and from 108 +/- 12 to 80 +/- 11 mmHg diastolic (mean +/- SD) (p less than 0.01). Plasma renin activity (PRA) increased significantly from 0.73 +/- 0.62 to 1.50 +/- 1.02 ng/ml/h (p less than 0.05). The same tendency was observed in malignant and renovascular hypertension. In primary aldosteronism (n = 2), blood pressure decreased but PRA did not increase. Hypotensive action and increased plasma renin activity by Ca2+ antagonist, Nifedipine, were clearly demonstrated in patients with hypertension.
给19例高血压患者舌下含服30毫克钙拮抗剂硝苯地平。原发性高血压患者（n = 14）收缩压从177±24降至123±13毫米汞柱，舒张压从108±12降至80±11毫米汞柱（均值±标准差）（p<0.01）。血浆肾素活性（PRA）从0.73±0.62显著增至1.50±1.02纳克/毫升/小时（p<0.05）。恶性高血压和肾血管性高血压患者也观察到同样趋势。在原发性醛固酮增多症患者（n = 2）中，血压下降但PRA未升高。钙拮抗剂硝苯地平对高血压患者的降压作用及血浆肾素活性升高作用得到明确证实。
